Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital drug development company, today announce the signing of a collaboration agreement. Under the agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no effective curative treatment is available.
Contributing to this collaboration, Delta4 will apply its proprietary computational and iterative big data analytics platform to identify novel therapeutic targets and signaling pathways as well as drug candidates for a rare autoimmune chronic liver disease. Based on the results provided by Delta4, 4P-Pharma will structure a tailored R&D maturation program with the focus to further characterize these candidates to demonstrate their potential for improving the treatment. Together, Delta4’s and 4P-Pharma’s teams aim to bring an innovative drug candidate to patients affected by this rare disease.
“4P-Pharma aims to bring breakthrough curative solutions with a strong scientific rationale to patients”, stated Revital Rattenbach, CEO of 4P-Pharma. “With this partnership, we will benefit from Delta4’s AI proprietary computational analytics platform to identify breakthrough drug candidates. Combined with our drug development expertise, together, we will accelerate the identification of drug candidates for patients affected by this rare liver disease. It underlines our shared commitment to bring breakthrough solutions to patients.”
“We are looking forward to joining forces with 4P Pharma to make a difference for patients who are suffering from a devastating disease”, commented Kurt Herpel, CEO, Delta4. Herpel added: “4P-Pharma has consistently proven the viability of their rigorous and focused approach to advancing promising drug candidates up the development pipeline. Specifically, we are excited about the opportunity to apply our platform to a new disease area and to work with 4P-Pharma to make a difference in the treatment of these liver-impaired patients.”
About 4P-Pharma
4P-Pharma is a French clinical-stage company founded in 2014, dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases. We aim to develop innovative programs with strong scientific rationale, sourced from the top academic research labs and AI-based biotechs. Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, the key differentiation of 4P-Pharma is the dual leverage of in-house R&D capabilities located within Pasteur Institute of Lille (France), combined with single product vehicle (SPV)-based deployment at clinical stage enabling big pharma clinical collaborations to facilitate market access.
www.linkedin.com/company/4p-pharma
@4P_Pharma
About Delta4
Delta4 is a digital drug discovery and development company, focusing on the discovery of novel indications for approved drugs. Delta4 combines in-silico drug discovery and big data analysis with extensive expertise in molecular biology and bioinformatics to a powerful proprietary drug discovery platform. Delta4 uses this platform for the discovery of promising drug leads. The drug leads thus generated are backed by a strong mechanistic hypothesis that significantly reduces the time to a clinical proof-of-concept of validated compounds.
www.linkedin.com/company/delta4ai
@Delta4ai
4P-Pharma press contact
Roselina Lam, Business Development and Licensing-in Manager
E-mail: roselina@4p-pharma.com
Delta4 press contact
Kurt Herpel, CEO
E-mail: kurt.herpel@delta4.ai
Pictured: Kurt Herpel, CEO of Delta4, and Revital Rattenbach, CEO of 4P-Pharma, celebrating the signature of a partnership agreement between Delta4 and 4P-Pharma in Paris (France).
About Autoimmune Chronic Liver Disease (ACLD)
Autoimmune chronic liver disease (ACLD) is a condition in which the immune system mistakenly attacks healthy liver cells, leading to chronic inflammation and liver damage. There are two main types of ACLD: autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC).
Prevalence
The exact prevalence of ACLD is unknown, but it is estimated that AIH affects 17.44 people per 1000,000 individuals, while PBC prevalence varies across geographical locations, but approximately affects 25-30 people per 100,000 worldwide. ACLD is more common in women than men and typically develops between the ages of 40 and 60.
Symptoms
The symptoms of ACLD can vary depending on the type and severity of the disease. Common symptoms include fatigue, abdominal pain, jaundice, itching, and weight loss. In severe cases, ACLD can lead to cirrhosis, liver failure, and liver cancer.
How It Affects People
ACLD can have a significant impact on the health and quality of life of those affected. Chronic inflammation and damage to the liver can cause ongoing symptoms, and the risk of liver failure or cancer can be a source of anxiety and stress. Treatment for ACLD typically involves medications to reduce inflammation and suppress the immune system, which can have side effects and require regular monitoring. In some cases, a liver transplant may be necessary.
It is important for individuals with ACLD to work closely with their healthcare providers to manage their condition, maintain a healthy lifestyle, and monitor for any potential complications. Support groups and counseling can also be helpful in managing the emotional and psychological impact of ACLD.
